Siemens Healthineers AG
SEMHF · Other OTC · USD
47,31USD
−1,26 (−2,60 %)Stand 11. Nov., 18:59
Kennzahlen
- Eröffnung
- 48,36
- Vortag
- 48,57
- Tagesspanne
- 47,31 – 48,36
- 52 Wochen
- 37,00 – 56,39
- Volumen
- 384
- Ø Volumen
- 3481
- Börsenwert
- 52,95 Mrd. $
- KGV
- 22,0
- Gewinn je Aktie (TTM)
- 1,97
- Dividendenrendite
- 2,3 %
- Beta
- 0,8
- Nächste Zahlen
- 4. Feb. 2027
Finanzen
| EUR | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Umsatz | 23,63 Mrd. | 23,42 Mrd. | 22,36 Mrd. | 21,68 Mrd. | 21,71 Mrd. |
| Herstellungskosten | 14,52 Mrd. | 14,37 Mrd. | 13,9 Mrd. | 13,97 Mrd. | 13,58 Mrd. |
| Bruttogewinn | 9,11 Mrd. | 9,05 Mrd. | 8,47 Mrd. | 7,71 Mrd. | 8,14 Mrd. |
| Forschung und Entwicklung | 1,97 Mrd. | 1,96 Mrd. | 1,92 Mrd. | 1,87 Mrd. | 1,79 Mrd. |
| Vertrieb und Verwaltung | 3,97 Mrd. | 3,64 Mrd. | 3,25 Mrd. | 3,4 Mrd. | 3,29 Mrd. |
| Operatives Ergebnis | 3,19 Mrd. | 3,44 Mrd. | 3,3 Mrd. | 2,44 Mrd. | 3,06 Mrd. |
| EBITDA | 4,49 Mrd. | 4,59 Mrd. | 4,22 Mrd. | 3,78 Mrd. | 4,26 Mrd. |
| Nettogewinn | 2,21 Mrd. | 2,15 Mrd. | 1,94 Mrd. | 1,51 Mrd. | 2,04 Mrd. |
| Gewinn je Aktie (verwässert) | 1,97 | 1,91 | 1,73 | 1,34 | 1,81 |
Bewertung
Letzte 12 Monate
- KGV
- 22,0
- Kurs-Umsatz-Verhältnis
- 2,1
- Kurs-Buchwert-Verhältnis
- 2,4
- PEG
- 6,0
- Bruttomarge
- 38,6 %
- Operative Marge
- 14,2 %
- Nettomarge
- 9,4 %
- Verschuldungsgrad
- 0,7
- EV/EBITDA
- 13,5
- Eigenkapitalrendite
- 11,7 %
- Kapitalrendite (ROIC)
- 7,1 %
- Free-Cashflow-Rendite
- 4,6 %
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | |
|---|---|---|---|---|---|
| Bruttomarge | 38,6 % | 38,6 % | 37,9 % | 35,6 % | 37,5 % |
| Operative Marge | 13,5 % | 14,7 % | 14,8 % | 11,3 % | 14,1 % |
| Nettomarge | 9,4 % | 9,2 % | 8,7 % | 7,0 % | 9,4 % |
| KGV | 19,9 | 23,4 | 28,6 | 35,8 | 22,8 |
| Kurs-Umsatz-Verhältnis | 1,9 | 2,1 | 2,5 | 2,5 | 2,1 |
| Kurs-Buchwert-Verhältnis | 2,2 | 2,4 | 3,1 | 3,0 | 2,4 |
| Verschuldungsgrad | 0,0 | 0,0 | 0,9 | 0,9 | 0,8 |
| Liquidität 3. Grades | 1,2 | 1,1 | 1,2 | 1,1 | 1,1 |
| Dividendenrendite | 2,5 % | 2,1 % | 1,9 % | 2,0 % | 2,0 % |
| Unternehmenswert | 41,61 Mrd. | 48,91 Mrd. | 69,15 Mrd. | 69,05 Mrd. | 61,86 Mrd. |
| EV/EBITDA | 9,3 | 10,6 | 16,4 | 18,3 | 14,5 |
| Eigenkapitalrendite | 11,2 % | 10,1 % | 10,7 % | 8,3 % | 10,3 % |
| Kapitalrendite (ROIC) | 7,4 % | 6,4 % | 6,9 % | 5,1 % | 5,6 % |
| Free-Cashflow-Rendite | 5,5 % | 4,5 % | 3,2 % | 1,8 % | 3,0 % |
Wachstum
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | |
|---|---|---|---|---|---|
| Umsatz | +0,9 % | +4,7 % | +3,2 % | −0,2 % | +20,7 % |
| Bruttogewinn | +0,7 % | +6,8 % | +9,8 % | −5,3 % | +17,0 % |
| Operatives Ergebnis | −7,2 % | +4,3 % | +35,2 % | −20,4 % | +10,3 % |
| Nettogewinn | +3,1 % | +10,6 % | +28,7 % | −26,0 % | +18,0 % |
| Gewinn je Aktie | +3,1 % | +10,4 % | +29,1 % | −26,0 % | +16,0 % |
| Freier Cashflow | +7,8 % | +28,0 % | +82,6 % | −30,8 % | −33,4 % |
| Dividende je Aktie | +4,8 % | +0,1 % | +0,0 % | +12,0 % | +9,3 % |
Analysten
Einstufungen · Hold
- 0Stark kaufen
- 0Kaufen
- 1Halten
- 0Verkaufen
- 0Stark verkaufen
Kursziel
Gerade nicht verfügbar.
Schätzungen
| FY 2027 | FY 2028 | FY 2029 | |
|---|---|---|---|
| Umsatz (Ø) | 25,16 Mrd. | 26,68 Mrd. | 28,23 Mrd. |
| Umsatz (Tief – Hoch) | 23,94 Mrd. – 25,84 Mrd. | 25,49 Mrd. – 27,47 Mrd. | 26,91 Mrd. – 29,03 Mrd. |
| Gewinn je Aktie (Ø) | 2,37 | 2,67 | 2,96 |
| Gewinn je Aktie (Tief – Hoch) | 2,22 – 2,45 | 2,51 – 2,77 | 2,78 – 3,07 |
| Analysten | 1 | 1 | 1 |
Quartalszahlen
Nächste Zahlen: 4. Feb. 2027| Nov. 2026 | Juli 2026 | Mai 2026 | Feb. 2026 | Nov. 2025 | Juli 2025 | Mai 2025 | Feb. 2025 | |
|---|---|---|---|---|---|---|---|---|
| Gewinn je Aktie · Erwartet | 0,76 | 0,60 | 0,58 | 0,52 | 0,81 | 0,63 | 0,61 | 0,49 |
| Gewinn je Aktie · Tatsächlich | 0,78 | 0,80 | 0,61 | 0,58 | 0,62 | 0,58 | 0,52 | 0,43 |
| Abweichung | +2,89 % | +32,28 % | +4,97 % | +9,92 % | −23,54 % | −7,68 % | −15,99 % | −10,77 % |
| Umsatz · Tatsächlich | 7,69 Mrd. | 6,58 Mrd. | 6,56 Mrd. | 6,34 Mrd. | 10,38 Mrd. | 6,67 Mrd. | 6,48 Mrd. | 5,68 Mrd. |
Dividenden und Splits
| Ex-Tag | Zahltag | Betrag |
|---|---|---|
| 9. Feb. 2026 | 10. Feb. 2026 | 1,19 |
| 20. Feb. 2025 | 21. Feb. 2025 | 1,00 |
| 19. Apr. 2024 | 23. Apr. 2024 | 1,01 |
| 16. Feb. 2023 | 20. Feb. 2023 | 1,01 |
| 16. Feb. 2022 | 18. Feb. 2022 | 0,97 |
| 15. Feb. 2021 | 17. Feb. 2021 | 0,80 |
| 13. Feb. 2020 | 17. Feb. 2020 | 0,87 |
| 6. Feb. 2019 | 8. Feb. 2019 | 0,80 |
Aktiensplits
–
Eigentümer
Institutionen
Gerade nicht verfügbar.
Insider-Geschäfte
–
Vergleichbare Unternehmen
2M6.DEMedtronic Plc91,00+0,44 %
300760.SZShenzhen Mindray Bio-Medical Electronics Co., Ltd.176,79−1,19 %
4543.TTerumo Corporation2.516,00+0,20 %
7733.TOlympus Corporation1.752,50−1,18 %
ABL.DEAbbott Laboratories98,88+1,02 %
BSX.FBoston Scientific Corporation40,28+2,81 %
DRW3.DEDrägerwerk AG & Co. KGaA109,60+9,93 %
GEHCGE HealthCare Technologies Inc.82,82−0,99 %
Über das Unternehmen
Siemens Healthineers AG, along with its affiliated companies, offers a global portfolio of diagnostic and therapeutic solutions, which it designs, produces, and markets to healthcare organizations worldwide. The company's operations are structured into four distinct divisions: Imaging, Diagnostics, Varian, and Advanced Therapies. The Imaging division specializes in advanced medical imaging technologies, encompassing magnetic resonance imaging (MRI), computed tomography (CT), X-ray equipment, molecular imaging techniques, and ultrasound systems. Within the Diagnostics division, the focus is on supplying in-vitro diagnostic solutions and services to healthcare professionals across various settings, including laboratory, molecular, and point-of-care environments. It also delivers laboratory workflow optimization tools and informatics solutions. The Varian segment is dedicated to oncology, furnishing cancer care technologies, comprehensive solutions, and support services to hospital and clinic oncology departments. This includes advanced workflow optimization through technology, expert clinical services and consultancy, as well as digital tools and applications designed to streamline and oversee patient treatment and therapy protocols. The Advanced Therapies division delivers products engineered to facilitate image-guided, minimally invasive procedures in fields such as cardiology, interventional radiology, and surgery. Its offerings extend to angiography systems and mobile C-arms, notably featuring a robotic-assisted platform for endovascular interventions involving coronary and peripheral vasculature. Beyond these core segments, Siemens Healthineers also offers a suite of supplementary services. These comprise managing equipment performance, clinical training and e-learning programs, asset management, and outsourced departmental services for both laboratories and wider healthcare institutions, alongside consulting and digital health solutions. Headquartered in Erlangen, Germany, Siemens Healthineers AG functions as a subsidiary of Siemens Aktiengesellschaft.
Führung
- Bernhard MontagPresident, Chief Executive Officer & Chairman of Management Board
- Jochen SchmitzChief Financial Officer & Member of Management Board
- Darleen CaronChief Human Resources Officer, Labor Director & Member of Management Board
- Elisabeth StaudingerMember of Management Board
- Astrid Kristine PlossMember of Supervisory Board, Head of Legal Advanced Therapies & Head of Legal Technology Excellence
- Arthur KaindlHead of Varian
- CEO
- Bernhard Montag
- Mitarbeitende
- 74.600
- Hauptsitz
- Forchheim, BV, DE
- Sektor
- Healthcare
- Branche
- Medical - Devices
- Börsengang
- 4. Aug. 2023
- Website
- siemens-healthineers.com
Nachrichten
- WSJ · 5. Nov., 2:08Siemens Healthineers to Rebrand as Healthineers as Diagnostics Carve-Out Begins
- Reuters · 5. Nov., 1:45Siemens Healthineers starts carve-out of diagnostics business
- Reuters · 5. Nov., 1:06Siemens Healthineers expects FY2027 revenue growth of 4%-5%
- Business Wire · 27. Sept., 13:51Sun Nuclear Announces Validated Adaptive QA Solution in Support of New Radiotherapy System, Accela, by Siemens Healthineers
- Defense World · 9. Sept., 1:41Siemens Healthineers (OTCMKTS:SEMHF) Stock Price Down 0.4% – Here’s What Happened
- Seeking Alpha · 23. Aug., 3:54Siemens Healthineers: Successful Investment, Updating For H2 2026
Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.